You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-CD47 therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)

Not yet recruiting
  • Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jul 17, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Apr 10, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

Relapsed/Refractory Lymphoma Trial in Beijing (Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection)

Recruiting
  • Relapsed/Refractory Lymphoma
  • Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Jan 10, 2022

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)

Not yet recruiting
  • P47-Phox, Deficiency of
  • Lentiviral vector transduced CD34+ cells
  • London, United Kingdom
    Great Ormond Street Hospital
Aug 2, 2022

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ublituximab
  • Fort Collins, Colorado
  • +1 more
May 26, 2023

Myelodysplastic Syndrome Trial in Suzhou (AK117, Azacitidine)

Recruiting
  • Myelodysplastic Syndrome
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 21, 2021

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Chemotherapy)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jan 27, 2022

Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Anti-CD33 CAR T-cells
  • Lymphodepletion Therapy
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Active, not recruiting
  • COVID-19
  • +3 more
  • Convalescent Plasma
  • Rochester, Minnesota
    Mayo Clinic
Jul 15, 2022

B-cell Lymphoma, B-cell Leukemia Trial in Kunming (anti-CD19 UCAR-NK cells)

Withdrawn
  • B-cell Lymphoma
  • B-cell Leukemia
  • anti-CD19 UCAR-NK cells
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

Solid Tumor, Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (Gentulizumab)

Recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Shanghai, Shanghai, China
  • +1 more
Jan 21, 2022

Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

Not yet recruiting
  • Follicular Lymphoma
  • Axicabtagene Ciloleucel
  • +5 more
  • (no location specified)
Sep 21, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)

Recruiting
  • CD7+ Acute Leukemia
  • CD7+ Lymphoma
  • anti-CD7 CAR-T
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Sep 18, 2022

Hiv Trial in Nice (plasma inflammatory markers, CD4/CD8 ratio)

Not yet recruiting
  • Hiv
  • plasma inflammatory markers
  • CD4/CD8 ratio
  • Nice, France
    CHU Nice
Jan 16, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Acute Myeloid Leukemia Trial in Hangzhou (AK117, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，Zhejiang University School of Medi
Jul 21, 2021